SwePub - sökning: WFRF:(Bingisser R)

Numrering	Referens	Omslagsbild	Hitta
1.	Leuppi, JD, et al. (författare) Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept 2005 Ingår i: Pulmonary Pharmacology & Therapeutics. - : Elsevier BV. - 1522-9629 .- 1094-5539. ; 18:2, s. 83-88 Tidskriftsartikel (refereegranskat)abstract Background: There are no predictors known that can identify COPD patients who will respond to treatment with ICS. Method: We investigated 30 patients (median age 65 (range 44-83, 12 females) with mild to moderately severe COPD. All patients had post bronchodilator FEV1/forced vital capacity ratio of less than 70% and a reversibility of less than 12% and 200 ml from baseline. We wanted to determine if airway responsiveness (AHR) to histamine and mannitol could predict who would respond to a 3-month course of ICS. Results: At baseline, all patients had AHR to histamine, but only 7 (23%) patients to mannitol. After 3 months of treatment with ICS, there was no significant change in spirometry or the quality of life when analysing all individuals together. However, FEV1 % predicted improved from 67% (IQR12) to 79% (IQR16) in mannitol positive patients; whereas it was unchanged in the mannitol negative patients. The difference in the mean change of FEV1% predicted between the two groups was 12 (IQR13.5) and this was highly significant (p=0.001). The improvement in quality of life (SGRQ 30 (IQR10.5) to 21 (IQR12; p=0.01) was only significant in the patients positive to mannitol. Conclusion: We propose that AHR to mannitol could predict ICS-responsiveness in mild to moderately severe COPD patients.

Leuppi, JD, et al. (författare)
Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept
2005
Ingår i: Pulmonary Pharmacology & Therapeutics. - : Elsevier BV. - 1522-9629 .- 1094-5539. ; 18:2, s. 83-88
Tidskriftsartikel (refereegranskat)abstract
- Background: There are no predictors known that can identify COPD patients who will respond to treatment with ICS. Method: We investigated 30 patients (median age 65 (range 44-83, 12 females) with mild to moderately severe COPD. All patients had post bronchodilator FEV1/forced vital capacity ratio of less than 70% and a reversibility of less than 12% and 200 ml from baseline. We wanted to determine if airway responsiveness (AHR) to histamine and mannitol could predict who would respond to a 3-month course of ICS. Results: At baseline, all patients had AHR to histamine, but only 7 (23%) patients to mannitol. After 3 months of treatment with ICS, there was no significant change in spirometry or the quality of life when analysing all individuals together. However, FEV1 % predicted improved from 67% (IQR12) to 79% (IQR16) in mannitol positive patients; whereas it was unchanged in the mannitol negative patients. The difference in the mean change of FEV1% predicted between the two groups was 12 (IQR13.5) and this was highly significant (p=0.001). The improvement in quality of life (SGRQ 30 (IQR10.5) to 21 (IQR12; p=0.01) was only significant in the patients positive to mannitol. Conclusion: We propose that AHR to mannitol could predict ICS-responsiveness in mild to moderately severe COPD patients.

Träfflista för sökning "WFRF:(Bingisser R) "

Avgränsa träffmängd